Skip to main content
. 2018 Mar 22;7(2):15. doi: 10.3390/antib7020015

Figure 4.

Figure 4

In vivo experiments. (a,b) EGFR+ HSC-2 tumor xenografts in mice were effectively treated with anti-EGFR DAR = 8 MMAU ADCs based on cetuximab. Mice were inoculated with tumor cells and treatment was given intravenously either with (a) 10 mg/kg or (b) 3 mg/kg ADC once weekly for four weeks (arrows). With the larger dose (a) the tumors shrunk permanently (follow-up of 100 days) and with the lower dose (b) the growth of the tumors was arrested in all but one mice (recurrence after 80 days). There were three mice in each treatment group. Error bars show the standard error of the mean. (c) Trastuzumab-MMAU ADCs (T-MMAU) were given to nude mice as single 10 mg/kg i.v. injection. DAR = 8 MMAU ADC showed 31% smaller area under curve (AUC) than DAR = 4 MMAU ADC. There were three mice in each treatment group. Error bars show the standard deviation.